Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
2(13%)
Results Posted
100%(13 trials)

Phase Distribution

Ph phase_1
2
13%
Ph phase_3
9
60%
Ph phase_4
2
13%
Ph phase_2
2
13%

Phase Distribution

2

Early Stage

2

Mid Stage

11

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
2(13.3%)
Phase 2Efficacy & side effects
2(13.3%)
Phase 3Large-scale testing
9(60.0%)
Phase 4Post-market surveillance
2(13.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

15

all time

Status Distribution
Active(2)
Completed(13)

Detailed Status

Completed13
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (13.3%)
Phase 22 (13.3%)
Phase 39 (60.0%)
Phase 42 (13.3%)

Trials by Status

recruiting17%
completed1387%
active_not_recruiting17%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT02016924Phase 2

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Active Not Recruiting
NCT06337032Phase 4

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

Recruiting
NCT00006604Phase 1

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

Completed
NCT01815736Phase 3

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Completed
NCT02603107Phase 3

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Completed
NCT02652624Phase 3

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Completed
NCT01705574Phase 3

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Completed
NCT01967940Phase 3

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Completed
NCT02246998Phase 4

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Completed
NCT01108510Phase 3

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Completed
NCT01363011Phase 3

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Completed
NCT00892437Phase 2

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Completed
NCT01106586Phase 3

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed
NCT01565889Phase 1

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Completed
NCT00272779Phase 3

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15